SBIA | Tomorrow - Enhanced Drug Distribution Security in 2023 Under the DSCSA Webinar

Don't miss out!

Receive this email as a forward? Subscribe to CDER SBIA industry updates. FDA | CDER | Small Business and Industry Assistance WEBINARS Enhanced Drug Distribution Security in 2023 Under the DSCSA TOMORROW: October 5, 2021  1:00 PM - 2:00 PM ET Register ABOUT THIS WEBINAR Please join us as FDA will: Discuss enhanced drug distribution security requirements that go into effect in 2023 under the Drug Supply Chain Security Act (DSCSA). Explain how enhanced drug distribution security will help protect patients from exposure to drugs that may be counterfeit, stolen, contaminated, or otherwise harmful. Summarize updates on implementation of supply chain security requirements under the DSCSA. TOPICS COVERED Pharmaceutical supply chain and distribution Drug traceability and verification Supply security requirements under the DSCSA Enhanced drug distribution security under DSCSA AUDIENCE Trading partners (Manufacturers, Repackagers, Wholesale Distributors, Dispensers (primarily Pharmacies), and Third-party Logistics Providers (3PLs)) Regulatory affairs professionals working on compliance with DSCSA requirements Solution providers or consultants working on DSCSA requirements Other Federal or State regulators CONTINUING EDUCATION Real-time attendance is required for the certificate of attendance which can be used in support of CEs for the following professional organizations.  Certificates are only available during the two weeks post-event. This course: has been pre-approved by RAPS as eligible for credits (appropriate to real-time attendance) towards a participant's RAC recertification upon full completion. has been pre-approved by SOCRA who accepts documentation of candidate participation in continuing education programs for re-certification if the program is applicable to clinical research regulations, operations or management, or to the candidate's clinical research therapeutic area. has been pre-approved by SQA as eligible for 1 non-GCP or non-GLP unit for every 1 hour of instructional time towards a participant's RQAP re-registration. has been approved by ACRP for continuing education in clinical research. ACRP will provide 1 ACRP contact hour for every 45-60 minutes of qualified material. The Small Business and Industry Assistance (SBIA) program in the Center for Drug Evaluation and Research provides guidance, education and updates for regulated industry. Register for Upcoming Training Watch Learning Library Recordings on YouTube Subscribe to CDER SBIA Email Updates Follow on LinkedIn Follow on Twitter

This is an automated message delivery system. Replying to this message will not reach the CDER SBIA staff. If you have comments or questions, contact us at CDERSBIA@fda.hhs.gov or 1-866-405-5367 or (301) 796-6707.   SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA